BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

304 related articles for article (PubMed ID: 20880361)

  • 1. Postoperative prostate-specific antigen nadir improves accuracy for predicting biochemical recurrence after radical prostatectomy: Results from the Shared Equal Access Regional Cancer Hospital (SEARCH) and Duke Prostate Center databases.
    Moreira DM; Presti JC; Aronson WJ; Terris MK; Kane CJ; Amling CL; Sun LL; Moul JW; Freedland SJ
    Int J Urol; 2010 Nov; 17(11):914-22. PubMed ID: 20880361
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Editorial Comment to Postoperative prostate-specific antigen nadir improves accuracy for predicting biochemical recurrence after radical prostatectomy: results from the Shared Equal Access Regional Cancer Hospital (SEARCH) and Duke Prostate Center databases.
    Viney R
    Int J Urol; 2010 Nov; 17(11):922-3. PubMed ID: 20969639
    [No Abstract]   [Full Text] [Related]  

  • 3. Nomogram Predicting Prostate Cancer-specific Mortality for Men with Biochemical Recurrence After Radical Prostatectomy.
    Brockman JA; Alanee S; Vickers AJ; Scardino PT; Wood DP; Kibel AS; Lin DW; Bianco FJ; Rabah DM; Klein EA; Ciezki JP; Gao T; Kattan MW; Stephenson AJ
    Eur Urol; 2015 Jun; 67(6):1160-1167. PubMed ID: 25301759
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Do nomograms designed to predict biochemical recurrence (BCR) do a better job of predicting more clinically relevant prostate cancer outcomes than BCR? A report from the SEARCH database group.
    Teeter AE; Presti JC; Aronson WJ; Terris MK; Kane CJ; Amling CL; Freedland SJ
    Urology; 2013 Jul; 82(1):53-8. PubMed ID: 23806388
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The effect of race on the discriminatory accuracy of models to predict biochemical recurrence after radical prostatectomy: results from the Shared Equal Access Regional Cancer Hospital and Duke Prostate Center databases.
    Moreira DM; Presti JC; Aronson WJ; Terris MK; Kane CJ; Amling CL; Sun LL; Moul JW; Freedland SJ
    Prostate Cancer Prostatic Dis; 2010 Mar; 13(1):87-93. PubMed ID: 19918263
    [TBL] [Abstract][Full Text] [Related]  

  • 6. What are the factors associated with short prostate specific antigen doubling time after radical prostatectomy? A report from the SEARCH database group.
    Teeter AE; Bañez LL; Presti JC; Aronson WJ; Terris MK; Kane CJ; Amling CL; Freedland SJ;
    J Urol; 2008 Nov; 180(5):1980-4; discussion 1985. PubMed ID: 18801519
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The percentage of prostate needle biopsy cores with carcinoma from the more involved side of the biopsy as a predictor of prostate specific antigen recurrence after radical prostatectomy: results from the Shared Equal Access Regional Cancer Hospital (SEARCH) database.
    Freedland SJ; Aronson WJ; Terris MK; Kane CJ; Amling CL; Dorey F; Presti JC
    Cancer; 2003 Dec; 98(11):2344-50. PubMed ID: 14635068
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Timing of Prostate-specific Antigen Nadir After Radical Prostatectomy and Risk of Biochemical Recurrence.
    Skove SL; Howard LE; Aronson WJ; Terris MK; Kane CJ; Amling CL; Cooperberg MR; Moreira DM; Freedland SJ
    Urology; 2017 Oct; 108():129-134. PubMed ID: 28735016
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Definition and preoperative predictors of persistently elevated prostate-specific antigen after radical prostatectomy: results from the Shared Equal Access Regional Cancer Hospital (SEARCH) database.
    Moreira DM; Presti JC; Aronson WJ; Terris MK; Kane CJ; Amling CL; Freedland SJ
    BJU Int; 2010 Jun; 105(11):1541-7. PubMed ID: 19912191
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A novel nomogram provides improved accuracy for predicting biochemical recurrence after radical prostatectomy.
    Xia HZ; Bi H; Yan Y; Yang B; Ma RZ; He W; Zhu XH; Zhang ZY; Zhang YT; Ma LL; Hou XF; Wirth GJ; Lu J
    Chin Med J (Engl); 2021 Jun; 134(13):1576-1583. PubMed ID: 34133352
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Prediction of outcome following early salvage radiotherapy among patients with biochemical recurrence after radical prostatectomy.
    Briganti A; Karnes RJ; Joniau S; Boorjian SA; Cozzarini C; Gandaglia G; Hinkelbein W; Haustermans K; Tombal B; Shariat S; Sun M; Karakiewicz PI; Montorsi F; Van Poppel H; Wiegel T
    Eur Urol; 2014 Sep; 66(3):479-86. PubMed ID: 24345725
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Prostate-specific antigen level, stage or Gleason score: which is best for predicting outcomes after radical prostatectomy, and does it vary by the outcome being measured? Results from Shared Equal Access Regional Cancer Hospital database.
    Mithal P; Howard LE; Aronson WJ; Kane CJ; Cooperberg MR; Terris MK; Amling CL; Freedland SJ
    Int J Urol; 2015 Apr; 22(4):362-6. PubMed ID: 25728968
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Re-calibration and external validation of an existing nomogram to predict aggressive recurrences after radical prostatectomy.
    Schroeck FR; Kattan MW; Moul JW; Aronson WJ; Presti JC; Terris MK; Kane CJ; Amling CL; Sun L; Freedland SJ
    BJU Int; 2010 Jun; 105(12):1654-9. PubMed ID: 19912203
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The CPC Risk Calculator: A New App to Predict Prostate-specific Antigen Recurrence During Follow-up After Radical Prostatectomy.
    Røder MA; Berg KD; Loft MD; Thomsen FB; Ferrari M; Kurbegovic S; Rytgaard HC; Gruschy L; Brasso K; Gerds TA; Kjær A; Brooks JD; Iversen P
    Eur Urol Focus; 2018 Apr; 4(3):360-368. PubMed ID: 28753827
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Comparison of observed biochemical recurrence-free survival in patients with low PSA values undergoing radical prostatectomy and predictions of preoperative nomogram.
    Berglund RK; Stephenson AJ; Cronin AM; Vickers AJ; Eastham JA; Klein EA; Guillonneau BD
    Urology; 2009 May; 73(5):1098-103. PubMed ID: 19278718
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Race as an outcome predictor after radical prostatectomy: results from the Shared Equal Access Regional Cancer Hospital (SEARCH) database.
    Freedland SJ; Amling CL; Dorey F; Kane CJ; Presti JC; Terris MK; Aronson WJ;
    Urology; 2002 Oct; 60(4):670-4. PubMed ID: 12385931
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Pretreatment prostate-specific antigen (PSA) velocity and doubling time are associated with outcome but neither improves prediction of outcome beyond pretreatment PSA alone in patients treated with radical prostatectomy.
    O'Brien MF; Cronin AM; Fearn PA; Smith B; Stasi J; Guillonneau B; Scardino PT; Eastham JA; Vickers AJ; Lilja H
    J Clin Oncol; 2009 Aug; 27(22):3591-7. PubMed ID: 19506163
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Three linked nomograms for predicting biochemical failure in prostate cancer treated with radiotherapy plus androgen deprivation therapy.
    López-Torrecilla J; Boladeras A; Cabeza MA; Zapatero A; Jove J; Esteban LM; Henriquez I; Casaña M; González-San Segundo C; Gómez-Caamaño A; Mengual JL; Hervás A; Muñoz JL; Sanz G
    Strahlenther Onkol; 2015 Oct; 191(10):792-800. PubMed ID: 26156249
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Race and prostate weight as independent predictors for biochemical recurrence after radical prostatectomy.
    Schroeck FR; Sun L; Freedland SJ; Jayachandran J; Robertson CN; Moul JW
    Prostate Cancer Prostatic Dis; 2008; 11(4):371-6. PubMed ID: 18427570
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Parameters derived from the postoperative decline in ultrasensitive PSA improve the prediction of radical prostatectomy outcome.
    Vesely S; Jarolim L; Schmidt M; Minarik I; Dusek P; Babjuk M
    World J Urol; 2013 Apr; 31(2):299-304. PubMed ID: 22684375
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 16.